- Investing Ideas
- U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
8
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
8 companies
Natera
Market Cap: US$45.9b
A diagnostics company, engages in the development and commercialization of molecular testing services worldwide.
NTRA
US$312.72
7D
13.6%
1Y
95.7%
Tempus AI
Market Cap: US$9.9b
Operates as a healthcare technology company in the United States.
TEM
US$55.69
7D
18.4%
1Y
-16.1%
Xeris Biopharma Holdings
Market Cap: US$1.5b
A commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois.
XERS
US$8.39
7D
2.4%
1Y
14.9%
AbbVie
Market Cap: US$438.2b
A research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
ABBV
US$250.09
7D
2.6%
1Y
25.9%
Teva Pharmaceutical Industries
Market Cap: US$42.1b
Develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
TEVA
US$36.48
7D
6.0%
1Y
119.8%
Sotera Health
Market Cap: US$5.4b
Provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally.
SHC
US$19.11
7D
5.5%
1Y
28.6%
Merck
Market Cap: US$323.0b
Operates as a healthcare company worldwide.
MRK
US$130.42
7D
1.9%
1Y
62.4%
Ligand Pharmaceuticals
Market Cap: US$5.9b
A biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide.
LGND
US$288.75
7D
-4.0%
1Y
89.1%